- Home
- SDA vs MDXH Comparison
SDA vs MDXH Comparison
Compare SDA & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SDA | MDXH |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | China | Belgium |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.5M | 203.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SDA | MDXH |
|---|---|---|
| Price | $2.05 | $3.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.75 | ★ $7.67 |
| AVG Volume (30 Days) | 85.5K | ★ 191.1K |
| Earning Date | 10-27-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $461,120,000.00 | $103,069,000.00 |
| Revenue This Year | $10.86 | $23.34 |
| Revenue Next Year | $13.07 | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.17 | ★ 21.68 |
| 52 Week Low | $1.54 | $1.35 |
| 52 Week High | $10.61 | $5.33 |
Technical Indicators
Market Signals| Indicator | SDA | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 53.92 | 42.64 |
| Support Level | $2.01 | $3.40 |
| Resistance Level | $2.18 | $3.74 |
| Average True Range (ATR) | 0.11 | 0.23 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 65.23 | 81.43 |
Price Performance
Historical ComparisonAbout SDA SunCar Technology Group Inc.
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.